Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial

Takashi Kadowaki(Toranomon Hospital), Soo Lim(Konyang University), Sang Yeoup Lee(Pusan National University), Wataru Ogawa(Kobe University), Toshimasa Yamauchi(The University of Tokyo), Tomoyuki Nishida, Usman Khalid(Novo Nordisk (Denmark)), Joakim Isendahl(Novo Nordisk (Denmark)), Kazuyuki Tobe(University of Toyama)

The Lancet Diabetes & Endocrinology

February 4, 2022

Cited by 319

|Nature Medicine|2002|4.2k

|Endocrine Reviews|2005|2.6k

|Nature Genetics|2021|2.4k

|The Lancet Diabetes & Endocrinology|2025|1.5k

|Circulation|2008|916

Related Papers